HomePTX • ASX
Follow
Prescient Therapeutics Ltd
Previous close
$0.050
Day range
$0.051 - $0.055
Year range
$0.044 - $0.11
Market cap
44.29M AUD
Avg Volume
1.30M
P/E ratio
-
Dividend yield
-
Primary exchange
ASX
Market news
.INX
0.11%
Financials
Income Statement
Revenue
Net income
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 969.90K | 54.62% |
Operating expense | 2.96M | 38.63% |
Net income | -1.81M | -25.69% |
Net profit margin | -186.59 | 18.71% |
Earnings per share | — | — |
EBITDA | -1.99M | -31.98% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 18.44M | -12.08% |
Total assets | 24.76M | -4.34% |
Total liabilities | 2.15M | 98.90% |
Total equity | 22.61M | — |
Shares outstanding | 805.32M | — |
Price to book | 1.67 | — |
Return on assets | -20.11% | — |
Return on capital | -22.03% | — |
Cash Flow
Net change in cash
(AUD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -1.81M | -25.69% |
Cash from operations | -1.74M | -73.55% |
Cash from investing | 2.00M | — |
Cash from financing | 9.08K | -99.83% |
Net change in cash | 261.34K | -93.98% |
Free cash flow | -1.18M | -44.53% |
About
Prescient Therapeutics Ltd is a clinical stage oncology company. The company is focused on the development of a universal CAR-T platform, enhanced CAR-T cell manufacturing & function and on two small molecule drug targeted therapies. Wikipedia
Founded
May 22, 1986
Website
Employees
3